Focus Diagnostics Home
 Home  About Focus Diagnostics  Employment  Contact Us
Test Listing New Tests Test Updates Certifications Client Services Account Setup Contact Us
 
Click the controls at right to expand & collapse the search function Open the search function Close the search function
Please select the first letter of the test you are interested in viewing or
click NEW for a complete listing of our newest assays.
Enter Test Name(s) / Code(s): Test Title Description Category Search:
 
All words must appear Any word can appear    
Reference Laboratory
Tests
 
51910
Kanamycin Level, BA print

Specimens collected just before or within 15 minutes of the next dose represent the TROUGH levels. Specimens obtained within 15-30 minutes after the end of I.V. infusion or 45-60 minutes after an IM injection or 90 minutes after oral intake represent the PEAK level.

This test is available for New York patient testing.

Bioassay
By report
1 mL serum
(minimum 0.5 mL)
FROZEN
3 to 4 days
80299
 
20610
Kappa/Lambda Light Chains Quantitative, NEPH (Serum) print

This assay detects both bound and free light chains in serum. In healthy individuals, over 99% of all serum light chains are bound to heavy chains of circulating immunoglobulins (IgG, IgA, IgM). Increased concentrations of both light chain types in conjunction with a normal ratio indicates polyclonal B cell stimulation, and characterizes chronic inflammatory diseases such as chronic active hepatitis. In contrast, an upward or downward shift in ratio caused by increased kappa chains or increased lambda chains, respectively, usually indicates a monoclonal gammopathy. In these situations, an immunoglobulin evaluation is recommended to identify and characterize any associated paraprotein.

For Free Kappa and Lambda Light Chains see unit code 20646.

This test is approved for New York patient testing.

Nephelometry
By report
1 mL serum
(minimum 0.5 mL)
2-8° C
1 to 5 days
83883 x 2
 
51685
Ketoconazole Level, BA print

Specimens collected just before or within 15 minutes of the next dose represent the TROUGH levels. Specimens obtained within 15-30 minutes after the end of I.V. infusion or 45-60 minutes after an IM injection or 90 minutes after oral intake represent the PEAK level.

Therapeutic levels:
 Peak serum4.0 mcg/mL

List all other antimicrobials being used to treat the patient.

This test is available for New York patient testing.



Please see the following technical sheet for more information:
 Antimicrobial Testing

Bioassay
By report
1 mL serum
(minimum 0.5 mL)
Red Top serum separator tubes not acceptable.
FROZEN
3 to 4 days
80299
 
43150
Kappa Light Chain Quantitative, NEPH (Urine) print

Both bound and free light chains in urine are detected by nephelometry; bound light chains are still linked to heavy chains of specific immunoglobulins (IgG, IgA, IgM). Approximately 25% of patients with multiple myeloma secrete free light chains only, and another 25% secrete free light chains plus bound light chains. An immunoglobulin evaluation test is recommended to identify and characterize any associated paraprotein.

This test is approved for New York patient testing.

Nephelometry
<1.5 mg/dL
5 mL urine
(minimum 5 mL)
2-8° C
1 to 5 days
83883
 
53150
Kappa/Lambda Light Chain Quantitative, NEPH (Urine) print

Both bound and free light chains in urine are detected by nephelometry; bound light chains are still linked to heavy chains of specific immunoglobulins (IgG, IgA, IgM). Approximately 25% of patients with multiple myeloma secrete free light chains only, and another 25% secrete free light chains plus bound light chains. An immunoglobulin evaluation test is recommended to identify and characterize any associated paraprotein.

This test is approved for New York patient testing.

Nephelometry
Kappa chains <1.5 mg/dL
Lambda chains <2.0 mg/dL
5 mL urine
(minimum 5 mL)
2-8° C
1 to 5 days
83883 x 2
 
Back To Top
 
First FDA Clearance of a 2009 H1N1 Test Given to Focus Diagnostics


FDA Issues Another Emergency Use Authorization for Commercial H1N1 Flu Test to Quest Diagnostics’ Focus Diagnostics


Focus Diagnostics provides the first commercial test for detecting the 2009 H1N1 influenza virus that the FDA has authorized for emergency use.


Focus Diagnostics receives NYSDOH exemption for Diagnostic Immunology and Serology testing services


Focus Diagnostics Launches Laboratory Test for Chikungunya Virus


 
   
Back to top  
   
©2010 - Focus Diagnostics - All Rights Reserved - Site Revision ID: WEB.FOCUSDX.C3 - Privacy Policy - Site Map